09.14.24 -- Cell & Gene Best Of August

The supply chain for mRNA-based cell and gene therapies presents unique challenges due to the sensitive nature of these products. Join Cell & Gene Live on September 24th for a digital discussion on how the industry can improve the efficiency, reliability, and scalability of the supply chain for mRNA-based therapies. Registration is free thanks to the support of Roche CustomBiotech.

Gene therapy products are complicated, and it can be hard to know at which step to measure potency. Here's how CSL Behring did it for Hemgenix.

Injectable drugs and implantable devices in contact with blood or spinal fluid are tested for endotoxins. This article reviews bacterial endotoxin testing and the LAL method.

Dark Horse Consulting Group joins Erin Harris to discuss Biologics License Applications (BLAs) of recent approvals and those currently under review.

In Part 2 of our series, we delve deeper into the crucial elements of transparency that prospective clients should consider when partnering with a CDMO, including analytics, documentation, and more.

AAV has become an increasingly popular vector for gene therapy applications, yet ongoing challenges related to process and analytical development often require significant expertise to navigate.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.